EMEA-002028-PIP01-16-M01
Key facts
Invented name |
Imfinzi
|
Active substance |
durvalumab
|
Therapeutic area |
Oncology
|
Decision number |
P/0256/2019
|
PIP number |
EMEA-002028-PIP01-16-M01
|
Pharmaceutical form(s) |
Concentrate for solution for infusion
|
Condition(s) / indication(s) |
Treatment of all conditions included in the category of malignant neoplasms (excluding central nervous system, haematopoietic and lymphoid tissue neoplasms)
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
AstraZeneca AB (Sweden)
Tel. +46 8553 27591 |
Decision type |
PM: decision on the application for modification of an agreed PIP
|